RecruitingNCT04137549

Registry Study on "Control Nocturnal Hypertension to Reach the Target "

Registry Study on "Control Nocturnal Hypertension to Reach the Target "(CONTROL-NHT)


Sponsor

Shanghai Institute of Hypertension

Enrollment

4,500 participants

Start Date

Dec 1, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Ambulatory blood pressure monitoring (ABPM) is a major innovation in the history of hypertension diagnosis. In clinical practice, the most well established indication for using ABPM is to identify patients who have high BP readings in the office but normal readings during usual daily activities outside of this setting or vice versa, and to identify varying 24-h BP profiles. However, in recent years, there has been increasing interest in BP values during sleep, and nocturnal BP is now recognized to be superior to daytime BP in predicting fatal and nonfatal cardiovascular events (stroke, myocardial infarction, and cardiovascular death), especially in medicated patients. The current direction in the management of hypertension is toward earlier and lower BP control for 24 hours, including the nocturnal and morning periods. Therefore, it may be of great significance to pay attention to the management of nocturnal blood pressure so as to reduce the increased cardiovascular risks. Information of nocturnal hypertensive patients defined by ABPM was prospectively registered nationwide, and then to investigate whether there was difference in cardiovascular prognosis according to the control of ambulatory nocturnal blood pressure.


Eligibility

Min Age: 50 YearsMax Age: 79 Years

Inclusion Criteria6

  • Age 50-79 years old
  • Clinical diagnosed hypertension with the use of antihypertensive drugs
  • Nocturnal hypertension ( nocturnal systolic blood pressure ≥ 130 mmHg and/or nocturnal diastolic blood pressure ≥ 80 mmHg)
  • A 24-hour ambulatory blood pressure monitoring was performed with validated equipment.
  • Willing to provide information about disease history and blood biochemical test data within 6 months.
  • Sign the informed consent

Exclusion Criteria3

  • Without antihypertensive drug use
  • Hospitalized hypertension patients
  • Non-compliant patient

Locations(1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04137549